Tirzepatide

Also called Mounjaro, Zepbound, LY3298176

Studied in:MetabolicWeight

Educational only, not medical advice. Dosaly reports what has been studied; it isn't a recommendation to use Tirzepatide or any amount of it. Talk to a clinician.

Approved by the FDA as a prescription medicine (Mounjaro for type 2 diabetes; Zepbound for weight management and obstructive sleep apnea) and by the EMA as Mounjaro.

Research applications

Type 2 diabetes (SURPASS trials, including head-to-head with semaglutide)
Obesity (SURMOUNT trials)
Obstructive sleep apnea (randomized trials)
GIP and GLP-1 receptor signalling

What studies have looked at, not proven uses.

What it is

Tirzepatide is a lab-made peptide that acts like two gut hormones, GIP and GLP-1. Large trials studied it in type 2 diabetes and obesity, and it's an approved medicine.

More detail

Tirzepatide is a synthetic 39-amino-acid peptide that activates two gut-hormone receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. It carries a fatty-acid chain that binds albumin and extends its action to about a week. Phase 3 trials in the SURPASS program studied it in type 2 diabetes, including a head-to-head trial against semaglutide, and the SURMOUNT trials studied it in obesity; later randomized trials looked at obstructive sleep apnea and other conditions. The most commonly reported side effects in these trials were gastrointestinal.

Evidence listed here

3 human studies

Results from cells and animals often don't carry over to people. How to read peptide research

Molecular info

Class: Lipidated peptide (GIP and GLP-1 receptor agonist)
Length: 39 amino acids
Sequence: H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys*-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Research areas: Metabolic, Weight

Lys* carries a fatty-acid chain (C20 diacid) that binds albumin; contains two Aib residues and ends in an amide.